+Compare
TYRA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
597.42M

TYRA Tyra Biosciences Forecast, Technical & Fundamental Analysis

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for TYRA with price predictions
08:00 PM EDT Sep 19, 2023

TYRA saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for TYRA moved out of overbought territory on September 05, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 21 similar instances where the indicator exited the overbought zone. In of the 21 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 12, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on TYRA as a result. In of 36 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for TYRA turned negative on September 08, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 18 similar instances when the indicator turned negative. In of the 18 cases the stock turned lower in the days that followed. This puts the odds of success at .

TYRA moved below its 50-day moving average on September 08, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TYRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TYRA advanced for three days, in of 120 cases, the price rose further within the following month. The odds of a continued upward trend are .

TYRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TYRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.504) is normal, around the industry mean (22.685). P/E Ratio (21.786) is within average values for comparable stocks, (131.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.923). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (316.663).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 402 to 424.75B. NVO holds the highest valuation in this group at 424.75B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was 27%, and the average quarterly price growth was 32%. BXPHF experienced the highest price growth at 300%, while SEEL experienced the biggest fall at -67%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was 29% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 63
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

TYRA is expected to report earnings to rise 16.13% to -36 cents per share on November 02

Tyra Biosciences TYRA Stock Earnings Reports
Q3'23
Est.
$-0.36
Q2'23
Beat
by $0.03
Q1'23
Beat
by $0.07
Q4'22
Beat
by $0.05
Q3'22
Beat
by $0.11
The last earnings report on August 10 showed earnings per share of -31 cents, beating the estimate of -33 cents. With 26.21K shares outstanding, the current market capitalization sits at 597.42M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2656 State Street
Phone
+1 619 728-4760
Employees
38
Web
https://www.tyra.bio
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCECX11.49N/A
N/A
Martin Currie Emerging Markets C
FQUAX15.76-0.01
-0.06%
AMG River Road Large Cap Value Select N
ISCIX35.70-0.16
-0.45%
Federated Hermes Intl Small-Mid Co IS
RGLHX19.96-0.09
-0.45%
American Funds Global Insight R-2E
SDGZX100.77-1.21
-1.19%
DWS Capital Growth R6

TYRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TYRA has been loosely correlated with ORMP. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TYRA jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TYRA
1D Price
Change %
TYRA100%
-5.45%
ORMP - TYRA
38%
Loosely correlated
-3.83%
SRNEQ - TYRA
36%
Loosely correlated
-1.15%
SAGE - TYRA
32%
Poorly correlated
-2.69%
FGEN - TYRA
31%
Poorly correlated
+10.50%
CARA - TYRA
31%
Poorly correlated
-7.73%
More